News & Observer Index, 1926-1992

Glaxo Inc.

Glaxo gets OK to sell new drug; Zofran stops nausea during chemotherapy - Ja 8 91 1D
Glaxo reassigns top executives - Ja 10 91 6C
Glaxo won't join Durham downtown project - Ja 15 91 5B
Glaxo plans to build $20 million facility in RTP - Ja 29 91 1D
Glaxo gives $1 million to NCCU for sciences - Fe 13 91 2B
Glaxo Inc. numbers revealing - Fe 24 91 1F
Glaxo taps Haber for senior post - Mr 12 91 1D
Glaxo denies reports it will cut retail prices - Mr 22 91 6C
Glaxo gives $1 million for Duke professorship - Ap 16 91 1D
Glaxo's darling targeted; Generic firm's suit challenges Zantac - My 12 91 1F
Glaxo shares take off - My 25 91 10C
Glaxo migraine drug (Imitrex) - My 26 91 1F
Glaxo Inc. child-care centers are planned; Construction slated to be finished in year - Jn 5 91 6C
Studies a shot in the arm for Glaxo migraine drug - Jn 9 91 2F
Glaxo stock falls after Barron's questions potential of big drugs - Jn 18 91 1D
Glaxo begins marketing new skin-disease drug - Jy 17 91 10C
Glaxo says ruling helps in patent squabble with SmithKline - Jy 30 91 1D
Glaxo opens new center for training sales force - Au 1 91 7C
Glaxo transfers building to UNC - Au 13 91 3B
RTP's Glaxo reports 17% surge in sales - Se 13 91 6C
Glaxo's ulcer drug could lead shift to over-the-counter sales - Se 15 91 3F
Glaxo retains right to develop Zantac for sale over counter - Oc 12 91 8C
Glaxo patent tested; Canadian firm eyes ulcer drug - Oc 22 91 1D
Glaxo gets go-ahead for migraine drug; Treatment expected to be a big seller - Oc 26 91 10C
Glaxo, Calif. firm team up on metabolism drug - Oc 30 91 9C
Glaxo eyes Kenly plant - No 3 91 1F
Ulcer patient claims Glaxo ties tainted judge - No 9 91 10C
Glaxo to buy plant Bristol-Myers closed (in Kenly) - No 13 91 9C
Glaxo completes deal for former Bristol plant - No 21 91 5C
Glaxo grants to help reduce infant deaths - No 22 91 5B
Former Glaxo worker (DONNELLY) admits selling samples; Sale of ulcer drug Zantac spanned 21
months - No 27 91 9C
Glaxo Inc. to reorganize roles of some executives - De 20 91 6C
212

Glaxo Inc.

Glaxo to begin testing AIDS inhibitor drug - Oc 20 88 22A
Glaxo starts construction of new research facility - No 1 88 2D
Glaxo planning more No 6 88 1I
Glaxo planning $90 million plant in Durham No 17 88 3C
Durham to get boost from Glaxo project No 18 88 1
Glaxo promotes vice president (Steigrod) No 24 88 8B
Glaxo on the air (Public awareness) - De 4 88 1I
Glaxo signs agreement to develop AIDS drug - De 6 88 1D
Glaxo reorganizing in Latin America - De 16 88 6B

Glaxo Inc.

Glaxo expects half of sales from Zantac, board told - Ja 9 90 1D
Glaxo gives $250,000 for art exhibit - Ja 18 90 1B
Glaxo decides against Durham plant; Firm still plans downtown office building for up to 300 workers - Ja 23 90 1B
Glaxo executive (Sanders) named director of parent firm - Fe 1 90 5C
Glaxo develops guide for pharmacy students - Fe 13 90 1D
Durham school may be bought by Glaxo - Fe 24 90 1B
Carpeting Glaxo floor huge job for Eatmans - Mr 9 90 7c
Ulcer drug boosts Glaxo profits - Mr 16 90 7C
Glaxo adds executive vice president (Ingram) - Mr 17 90 8C
President honors Glaxo volunteers - Mr 23 90 2B
Sanford, Helms win tax break for Glaxo - Ap 25 90 1
Glaxo finds profits in stepped-up effort to lobby Congress - Ap 26 90 1B
Glaxo to update analysts - My 6 90 1F
Council agrees to sell school land to Glaxo - Jn 1 90 2B
Glaxo Holdings close to getting approval for drugs - Jn 1 90 7C
Glaxo unit president elected to firm's board - Jn 14 90 7C
Glaxo examines new drug for ulcers - Jn 17 90 4F
Glaxo to seek approval for migraine treatment - Jn 26 90 1D
Glaxo Inc. begins work on new training center - Jn 28 90 6C
Glaxo formally asks FDA to approve drug (sumatriptan for migraine) - Jy 3 90 1D
Way clear for Glaxo to buy Durham school - Jy 11 90 2B
Glaxo agrees to cut drug prices for state Medicaid programs - Jy 25 90 5B
Glaxo, Gilead plan may yield new cancer drugs - Jy 27 90 5C
Shaw boosts its efforts in sciences - Jy 27 90 5B
Glaxo parent plans $800 million complex - Au 10 90 5C
Glaxo buys license from RTI, sells drug - Au 30 90 9C
Glaxo's 'Sir Paul' center - Se 2 90 1F
Ulcer drug lifts profits for Glaxo - Se 21 90 7C
British executive (Sykes) to direct Glaxo RTP center - Oc 4 90 6C
Glaxo to shift RTP focus from heart research - Oc 11 90 6C
Glaxo Inc. - A chronology - Oc 14 90 12A
RTP baby Glaxo grows up; Drug firm crowns decade of growth with new center - Oc 14 90 1
Amid changes, Glaxo unveils research center - Oc 19 90 6C
The urban image: A $450 million experiment in productivity; Glaxo's campus hopes to get results from good design - No 4 90 1H
Glaxo is teller's pet - No 18 90 1F
Glaxo, FBI foil attempt to sell firm rival's secrets - No 23 90 7C
Delayed Glaxo decision worries backers of Durham's downtown - No 24 90 1B
Rival drug giants face secrets deal anew - No 24 90 1B
Glaxo Canada to help develop, sell cancer and virus treatments - No 29 90 6C
Glaxo presentation impresses analysts - De 5 90 6C
Glaxo seeks OK for migraine tablet - De 18 90 1D

Glaxo Inc.

Glaxo expands (Photo) - Ja 10 89 1D
New ulcer drug could slow Glaxo's Zantac sales growth slightly - Ja 14 89 8B
Glaxo gives $80,000 to 37 arts agencies - Ja 28 89 2C
Burroughs Wellcome has direction; Glaxo still narrowing choices - Ja 29 89 3J
Idaho company agrees to head Glaxo project - Fe 10 89 5B
Offices on same floor - Fe 26 89 1I
Glaxo names president of Latin American operations - Mr 2 89 10B
Glaxo endows Wake artists program - Mr 23 89 10T
Helms in Tasmania as Glaxo seeks edge in 'opium war' - Mr 25 89 1C
Glaxo effort aimed at new drugs - Ap 26 89 5B
Editorial: Checking a gift horse - Ap 29 89 16A
Glaxo says progress made in developing new drugs - My 6 89 8B
Mario promoted at Glaxo Holdings - My 10 89 5B
Glaxo chief says new chairman will come from outside firm - My 24 89 6B
Glaxo chief (Mario) says new drugs will build the future of firm - My 28 89 1I
Glaxo reports $1.5 billion in sales, hiring increase - Jn 2 89 6B
Glaxo gives grant for AIDS education program - Jn 9 89 8B
Glaxo may form venture capital fund to aid in product development - Jn 14 89 5B
Glaxo might be interested in Robins plant - Jn 17 89 5B
Glaxo to announce plant construction - Jn 17 89 5B
Glaxo expected to name chief executive officer - Jn 21 89 6B
New Glaxo chief (Sanders) ready for business - Jn 22 89 6B
Glaxo planning first public image campaign - Jy 6 89 7B
(Zebulon) Recreation program gets grant - Jy 6 89 2T
Glaxo research executive (Cuatrecasas) to leave drug company - Jy 11 89 1D
Theater receives grant from Glaxo - Au 10 89 4T
Glaxo pledges $75,000 for Duke minorities - Au 16 89 10A
Glaxo Inc. - a chronology - Se 10 89 17A
In narrowing its focus, Glaxo loses its star scientist - Se 10 89 1
Glaxo a step ahead on moving research site - Se 17 89 1I
Sale of ulcer drug helps increase net income of Glaxo by about 20% - Se 20 89 5B
Glaxo seeks follow-up for profitable anti-ulcer drug - Oc 15 89 1I
Glaxo gives contribution to series - No 2 89 9T
Glaxo looks outside for new prescription drugs - No 3 89 8B
Glaxo presents first profit-sharing awards - No 17 89 7B
Glaxo plans incinerator for complex - No 18 89 2C
Glaxo begins program to help asthma victims - No 29 89 12A
Glaxo ends development of potentially risky ulcer drug - De 5 89 1D
Glaxo tests lab in a lab - De 10 89 1G
Glaxo signs agreement on cystic fibrosis drug - De 14 89 5C
No-nonsense boss at Glaxo is leery of top-heavy firms - De 24 89 1G

Glaxo Inc.

RTP company may buy (old Zebulon Elementary) school - Jn 22 85 1C
Glaxo receives FDA approval to sell new antibiotic (Fortaz) - Jy 20 85 8B
Glaxo looking beyond Zantac - Au 27 85 1D
Glaxo plans to add research unit at RTP - Se 19 85 7B
Zantac boosts Glaxo's sales to healthy 78% gain - No 1 85 5C
Glaxo sues to block generic version of drug (Ceftazidime) No 16 85 12B
Glaxo loses ruling on generic drug No 21 85 7B

Glaxo Inc.

Glaxo will build large RTP center - Ja 1 88 1
Glaxo to market (heart) drugs for Hoffmann-LaRoche - Ja 8 88 5B
Casual drug firm president well-grounded in industry - Ja 19 88 2D
Glaxo on industry's fast track; Analysts unconvinced; 'one-product company' relies on Zantac - Ja 19 88 1D
Glaxo to change design of its drug packaging - Mr 2 88 5B
Company policies vary on minority employment - Mr 29 88 4D
Glaxo donates to Poland - Ap 3 88 1I
Glaxo moves to broaden sales base - Ap 6 88 6B
Glaxo forms units to sell various drugs - Ma 24 88 5D
Glaxo gives $150,000 for Tammy Lynn Center - Ma 24 88 2C
Glaxo executive glad to be back in Triangle - Jn 8 88 5B
Glaxo tops sales record in only 10 months - Jn 9 88 7B
Glaxo executive (Mario) promoted to top post - Jn 14 88 1D
Glaxo giving $250,000 toward center at Duke (for executive education programs) - Au 13 88 8B
Glaxo research unit to move - Au 17 88 7B
Glaxo Inc. gives Duke $1 million for heart center - Se 21 88 2C
Glaxo to give $1 million for endowment at Duke - Se 21 88 7B
Glaxo chairman (Mario) moving from Triangle to London - Oc 18 88 1D

N&O Index Card Listings